Loading...
NPI 1447230420 · East Syracuse, NY · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Jeffrey Kirshner is a hematology & oncology physician provider located in East Syracuse, New York. This profile covers 67 Medicare and 2 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Jeffrey Kirshner |
| Address | 5008 Brittonfield Pkwy |
| City | East Syracuse |
| State | NY |
| ZIP | 13057 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | January 18, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.2M |
| Medicaid | $290 |
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
67 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 12,600 | $40 | $554.4K |
| J9299 | Injection, nivolumab, 1 mg | 19,070 | $20 | $457.7K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 9,000 | $40 | $342K |
| J1930 | Injection, lanreotide, 1 mg | 3,840 | $40 | $165.1K |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 4,380 | $40 | $162.1K |
| J0897 | Injection, denosumab, 1 mg | 5,760 | $20 | $103.7K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 510 | $100 | $50.3K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 20,290 | $1 | $40.6K |
| J9305 | Injection, pemetrexed, not otherwise specified, 10 mg | 2,910 | $10 | $34.9K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 27,750 | $1 | $27.8K |
Showing 1–10 of 67
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 67 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
67 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 22 | 60 | 9,900 | $40 | $505.5K |
| J9144 | 14 | 20 | 10,440 | $40 | $499.4K |
| J9299 | 4 | 10 | 14,670 | $20 | $438.2K |
| J1930 | 2 | 10 | 3,840 | $40 | $241.5K |
| J1561 | 16 | 40 | 3,100 | $40 | $234.9K |
| J0897 | 110 | 490 | 2,820 | $20 | $84.4K |
| Q5111 | 16 | 20 | 400 | $110 | $50.9K |
| J3490 | 14 | 120 | 60 | $470 | $50.8K |
| J1439 | 56 | 90 | 39,750 | $1 | $42K |
| J0881 | 22 | 80 | 13,100 | $1 | $41K |
Showing 1–10 of 67
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
2 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 20 | $20 | $260 |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 30 | $1 | $30 |
How this provider's Medicaid billing volume and revenue compare to other New York providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. New York median
2 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 180 | 200 | 630 | $150 | $338K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 1,177 | 1,420 | 300 | $20 | $38.8K |
Other providers in the same ZIP code as Jeffrey Kirshner, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Syracuse Endoscopy Associates, LLC | NY | Endoscopy Clinic/Center | $560.3K | $1.1M |
| K&a Radiologic Technology Services Inc | NY | Portable X-ray and/or Other Portable Diagnostic Imaging Supplier | $638.2K | $89.1K |
| Upstate Orthopedics Ambulatory Surgery Center LLC | NY | Ambulatory Surgical Clinic/Center | $402.5K | $83.6K |
| Benny Wong | NY | Hematology & Oncology Physician | $403.7K | $7.3K |
| Vinod Varki | NY | Hematology & Oncology Physician | $388.7K | $0 |
| Aref Agheli | NY | Hematology & Oncology Physician | $364.3K | $1.8K |
| Jeffrey Cizenski | NY | Dermatology Physician | $290.7K | $0 |
| Robert Sherman | NY | Orthopaedic Surgery Physician | $258.5K | $5K |
| Traian Anghel | NY | Clinical Cardiac Electrophysiology Physician | $256K | $190 |
| Hassan Shukri-mahmod | NY | Neurology Physician | $215.9K | $12.8K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.